Press Releases

October 2, 2026 Celcuity Appoints David Gryska To Its Board Of Directors
Read More
September 30, 2026 Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Read More
September 1, 2026 Celcuity To Participate in Upcoming Investor Conferences
Read More
August 26, 2026 Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Read More
August 13, 2026 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Read More
August 6, 2026 Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
Read More
July 30, 2026 Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Read More
July 14, 2026 Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Read More
June 3, 2026 Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Read More
June 3, 2026 Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Read More